Biomedicine & Pharmacotherapy 2008-01-01

Simultaneous determination of serum concentrations of levodopa, dopamine, 3-O-methyldopa and alpha-methyldopa by HPLC.

Chiara Muzzi, Erica Bertocci, Lucia Terzuoli, Brunetta Porcelli, Ilaria Ciari, Roberto Pagani, Roberto Guerranti

Index: Biomed. Pharmacother. 62 , 253-258, (2008)

Full Text: HTML

Abstract

Levodopa is the medication of choice for Parkinson's disease. The biological complexity of levodopa and of its main derivatives makes their determination important in the clinical field. The aim of this study was to develop an HPLC method for the simultaneous determination of serum concentrations of levodopa, dopamine, 3-O-methyldopa and alpha-methyldopa. We compared UV and fluorimetric detection of native and derivatised compounds. Though less sensitive than other methods, UV detection is important to exclude naturally fluorescent, interfering substances. Fluorimetric detection of derivatised compounds is more sensitive than UV detection. Since 3-O-methyldopa does not react with the derivatising agent 1,2-diphenylethylenediamine, it cannot be detected. For simultaneous determination of the four compounds after pharmacological treatment of patients we therefore advise fluorimetric detection of the native compound.


Related Compounds

Related Articles:

Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.

2011-02-15

[Mov. Disord 26 , 543-546, (2011)]

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

2010-05-01

[Clin. Neuropharmacol. 33(3) , 135-41, (2010)]

Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.

2012-06-01

[Eur. J. Neurol. 19(6) , 820-6, (2012)]

Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.

2007-01-01

[J. Neural Transm. Gen. Sect. 114(11) , 1457-62, (2007)]

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

2009-10-01

[Clin. Ther. 31(10) , 2258-71, (2009)]

More Articles...